已收盤 11-20 16:00:00 美东时间
-2.430
-2.97%
CG Oncology, Inc. ( NASDAQ:CGON ) shareholders (or potential shareholders) will be happy to see that the President...
11-21 22:52
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
11-19 19:40
11月19日,CG Oncology(CGON)收涨1.34%,报80美元,成交额1.43亿美元,市值71.46亿美元。 行情数据 • 开盘价:79.12美元...
11-19 05:59
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从11美元升至11.25美元;康托·菲茨杰拉德:维持Cypherpunk Technologies"超配"评级,目标价从4.9美元升至5美元
11-18 15:28
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.
11-17 21:20
英伟达盘后迎Q3财报大考!全球瞩目临时CEO首秀;光通信股盘前急升,Lumentum升逾8%!特朗普拟推进光收发器进口限制;段永平Q3砍仓英伟达,加码特斯拉>>
11-17 21:04
CG Oncology涨14%,三期试验显著降低膀胱癌复发风险;泰勒斯升12%,收到溢价约60%收购提案;
11-17 09:26
CG Oncology shares are trading higher after the company announced PIVOT-006 achieved its primary endpoint.
11-16 21:45
CG Oncology announced positive results from the PIVOT-006 Phase 3 trial, showing cretostimogene reduced the risk of bladder cancer recurrence by 68% (HR 0.32, p<0.0001) with no Grade 3+ adverse events. The trial involved 367 patients with intermediate-risk and high-grade Ta NMIBC. The data will support a BLA submission in Q2 2027 and broaden the label for BCG-unresponsive NMIBC by March 2027. These findings highlight cretostimogene's potential as...
11-16 13:00
11月11日,CG Oncology(CGON)收跌2.81%,报72.64美元,成交额5968.91万美元,市值64.88亿美元。 行情数据 • 开盘价:7...
11-11 06:01